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  Substrate specific protein 
degradation mediated by the ubiquitin (Ub) 
proteasome system (UPS), is crucial for the 
proper function of the cell. Proteins are 
specifically recognized and ubiquitinated by the 
Ub ligases (E3s), and are then degraded by the 
proteasome. BTB proteins act as the substrate 
recognition subunit that recruits their cognate 
substrates to the Cullin (Cul) 3-based 
multi-subunit E3s. Recently, it was reported 
that missense mutations in KLHL7, a 
BTB-Kelch protein, are related to autosomal 
dominant Retinitis Pigmentosa (adRP). 
However, the involvement of KLHL7 in the 
UPS and the outcome of the adRP causative 
mutations were unknown. In this study, we 
show that KLHL7 forms a dimer, assembles 
with Cul3 through its BTB and BACK domains, 
and exerts E3 activity. K48- but not K63-linked 
poly-ubiquitin chain co-localized with KLHL7, 
which increased upon proteasome inhibition 
suggesting that KLHL7 mediate protein 
degradation via UPS. An adRP causative 
missense mutation in the BACK domain of 
KLHL7 attenuated only the Cul3 interaction 
but not dimerization. Nevertheless, the 
incorporation of the mutant as a hetero dimer 
in Cul3-KLHL7 complex diminished the E3 
ligase activity. Together, our results suggest 
that KLHL7 constitutes a Cul3-based E3 and 
that the disease-causing mutation inhibits ligase 
activity in a dominant negative manner, which 
may lead to the inappropriate accumulation of 
the substrates targeted for proteasomal 
degradation. 
 Covalent attachment of ubiquitin (Ub) 
onto proteins is involved in the regulation of a 
wide array of cellular phenomena, ranging from 
the cell cycle to stress response and DNA damage 
repair (1,2). Proteins targeted for ubiquitination 
are attached with either a single Ub or a poly-Ub 
chain, formed by the coupling of Ub molecules via 
one of the seven Lys residues or the N terminus of 
the first Ub molecule and the C terminus of the 
second. Poly-Ub chain via the Lys48 is known to 
act as a degradation signal, which is recognized by 
the proteasome and consequently leads to the 
degradation of the ubiquitinated protein. Lys63 
linkage poly-Ub chains are involved in 
non-proteolytic regulation such as signal 
transduction and damaged DNA repair (3) and 
autophagy-mediated protein degradation (4). 
Other modes of the Ub chain are present in 
eukaryotic cells (5), but the functions of each form 
are yet to be elucidated.  
In the ubiquitination reaction, Ub is 
first activated by the Ub-activating enzyme E1, 
and then carried by the Ub-conjugating enzyme 
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E2 to the Ub ligase E3, where the Ub is attached 
onto a lysine residue of the specific substrate of 
the E3s (1,2). The substrate specificity of this 
pathway is determined by the E3s of which the 
Cullin-RING ligases (CRLs) constitute the largest 
subclass. CRLs are multi-subunit complexes 
where the enzymatic core Rbx1/Roc1, and 
substrate recognition modules each assemble onto 
the C- and N-terminus of a Cullin (Cul1, Cul2, 
Cul3, Cul4A, Cul4B, Cul5 and Cul7) (6-10). The 
most well-characterized CRL is the SCF Ub ligase, 
comprised of Cul1, Roc1, an F-box family protein 
and Skp1. The F-box protein, that recruits the 
substrate, binds to the adaptor protein Skp1, which 
in turn binds onto Cul1(11-14). In Cul3-based 
CRLs, instead of F-box proteins, BTB (Bric-à-brac, 
Tramtrack and Broad complex)/POZ (poxviruses 
and zinc finger) family proteins are employed as 
the substrate adaptor (15-18). There are more than 
180 BTB proteins encoded in the human genome 
(19), and some of them have been related to 
substrate-targeting in Cul3 complexes. BTB 
proteins bind to Cul3 through the BTB domain 
and the adjacent ‘3-box (Cul3-interactin box)’ 
region, an element involved in facilitating this 
interaction (20). Whilst interacting with Cul3, 
BTB proteins recruit substrates with their 
additional protein-protein interaction domain, such 
as the Kelch and MATH domains. 
Of the BTBs involved in ubiquitination 
processes, the BTB-Kelch protein Keap1 is the 
best characterized. By regulating the turnover of 
the transcription factor Nrf2, Keap1 has an 
important role in the cellular defense mechanism 
for oxidative and xenobiotic stresses (21,22). 
Another two BTB-Kelch proteins, KLHL9 and 
KLHL13 are involved in the cell cycle by 
targeting Aurora B, thereby regulating cytokinesis	 
(23). The emerging roles of BTB family proteins, 
and the discovery of mutations in BTB proteins 
that are responsible for diseases, such as gigaxonin 
for giant axonal neuropathy patients (24) and 
KLHL9 in autosomal dominant distal myopathy 
(25), have set forth the importance of BTB 
proteins. 
Recently, three disease-causing 
missense mutations in the BACK domain of 
KLHL7, a BTB-Kelch protein, were found in 
patients with autosomal dominant Retinitis 
Pigmentosa (adRP) (26,27). RP are a genetically 
heterogeneous group of progressive retinal 
dystrophies, resulting in degeneration of rod and 
cone photoreceptors. Patients experience night 
blindness and visual field loss, often leading to 
complete blindness. RP can be inherited in an 
autosomal dominant, autosomal recessive, and 
X-linked manner (28,29). 
 Here, we report that KLHL7 forms 
Cul3-KLHL7 Ub E3 ligase in cells, and that an 
adRP causative mutation, A153V, leads to the 
attenuation of the E3 ligase activity of 
Cul3-KLHL7 in a dominant negative manner. Our 
results provide molecular insights into the function 
of KLHL7 and the outcome of an adRP causative 
mutation. 
 
EXPERIMENTAL PROCEDURES 
 
Expression Plasmids— Epitope-tagged full length 
KLHL7 was amplified from human placenta 
cDNA library using Phusion DNA polymerase 
(Finnzymes) and cloned into EcoRI and NotI sites 
of pcDNA3 or pEFBOS (-) vectors. Cul3 and Ub 
were generated likewise, and cloned into EcoRI 
and XhoI sites. Deletion mutants of KLHL7 were 
generated by a PCR-based method. The S150N, 
A153V and A153T amino-acid substitutions were 
introduced by Quick-Change site-directed 
mutagenesis method using overlapping primers. 
The PCR amplified coding regions of Cul3, 
KLHL7 (wild-type and mutants) and Ub were 
verified by sequence analyses. 
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Cell Culture, Transfection and Treatment— 
HCT116 cells were cultured in Dulbecco’s 
modified Eagle’s medium (low glucose) (WAKO) 
supplemented with 10 % fetal bovine serum, 1 % 
Non-Essential Amino Acids Solution (NEAA) 
(Gibco) and 1 % penicillin streptomycin (Gibco) 
in a 37 °C incubator with 5 % CO2. HeLa cells 
were cultured as above without NEAA. ATG5+/+: 
GFP-LC3 and ATG5-/-: GFP-LC3 MEFs (30) were 
cultured in medium without NEAA, supplemented 
with 0.8 % Puromycin. Transfections were carried 
out using FuGENE 6 Transfection reagent (Roche), 
Lipofectamine 2000 (Invitrogen) or Multifectam 
(Promega) according to the manufacturers’ 
specifications. For proteasome inhibition, cells 
were treated with MG132 (Z-Leu-Leu-Leu-H) 
(Peptide institute) for 1 hr at 20 µM. For lysosome 
inhibition, cells were treated with NH4Cl (Wako) 
for 1 hr at 10 mM. 
Antibodies— The following antibodies were used 
for immunoblot analyses: anti-FLAG monoclonal 
(Sigma: M2), rabbit polyclonal (Rockland), 
anti-HA monoclonal (Covance: HA. 11), 
polyclonal (Bethyl), anti-cMyc monoclonal (Santa 
Cruz: 9E10) and anti-Cul3 rabbit polyclonal 
antibodies. Anti-Cul3 antibody was raised using 
recombinant His-tagged Cul3. Anti-Roc1 rabbit 
polyclonal antibody has previously been described	 
(31). Peroxidase-conjugated anti-rabbit and 
anti-mouse antibodies (Jackson Immuno Research 
Laboratory) were used as secondary antibodies. 
For immunocyochemical analyses, anti-FLAG 
(Sigma: M2), anti-HA rabbit polyclonal (Bethyl), 
anti-multi-Ub (MBL: FK2), anti-Ub 
Lys48-Specific (Millipore: Apu2), anti-Ub 
Lys63-Specific (Millipore: Apu3) and anti-GFP 
rabbit polyclonal (MBL) were used with Alexa 
Fluor 488 and Alexa Fluor 568 conjugated 
anti-rabbit and anti-mouse antibodies (Invitrogen 
Molecular Probes). 
Immunoprecipitation and Immunoblot analyses— 
Cells were lysed with ice cold lysis buffer (20 mM 
Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM 
Ethylenediaminetetraacetic acid (EDTA), 0.5 % 
CHAPS (Sigma), 1 mM dithiothreitol (DTT)). The 
supernatant was subjected to immunoprecipitation 
with anti-FLAG M2 agarose or anti-HA agarose 
beads (Sigma) and incubated at 4 °C overnight. 
The beads were then washed with lysis buffer 
containing 750 mM NaCl and 0.2 % CHAPS. The 
protein samples were added to SDS sample buffer, 
boiled for 5 mins, and immunoblotted using 
Western Lightning Plus-EDL reagent (Perkin 
Elmer). 
Immunofluorescence analyses— HeLa cells were 
cultured on coverslips and were transfected with 
various expression plasmids. The cells were fixed 
in 4 % paraformaldehyde in PBS for 10 mins, 
permeabilized and blocked in 0.5 % Triton X-100, 
5 % BSA in PBS for 30 min. The coverslips were 
then immersed in primary antibodies diluted in 
5 % BSA in PBS followed by secondary 
immunofluorescent antibodies diluted in 5 % BSA 
in PBS. Nuclei were stained with Hoechst 33342 
(Invitrogen Molecular Probes). The Coverslips 
were mounted onto slides using Fluoromount/Plus 
mounting solution (Diagnostic BioSystems) and 
images were obtained using a fluorescent 
microscope (Keyence: Model BZ-9000). 
In vitro ubiquitination assays— Cul3-KLHL7 
complex was immunoprecipitated from cells 
expressing FLAG-KLHL7 and eluted in 1x FLAG 
peptide (Sigma) in TBS. The purified protein was 
incubated at 30 °C for 1 or 2 hours with 10 µg of 
Ub (Sigma), 0.2 µl of Ub-activating enzyme 
UBE1 (Boston Biochem), 0.2 µg of 
Ub-conjugating enzyme His-UBC4 purified from 
E. Coli, in reaction buffer (50 mM Tris-HCl, pH 
7.5, 150 mM NaCl, 10 mM MgCl2, 0.5 mM DTT) 
either with or without 5 mM ATP at the final 
volume of 50 µl. The reaction was stopped by the 
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addition of SDS sample buffer, followed by 
boiling for 5 mins at 100 °C. The reaction 
mixtures were then subjected to Immunoblot 
analyses with anti-multi-Ub (MBL: FK2) antibody 
to assess poly-Ub chain formation. 
 
RESULTS 
 
KLHL7 forms Cullin3-based complexes. Some 
BTB-BACK-Kelch proteins have been reported to 
function as the substrate recognition subunits of 
Cul3-based CRLs. However, whether KLHL7 
associates with Cul3 or functions as an E3 ligase 
is unknown. To investigate whether KLHL7 forms 
Cul3-based complex, we expressed FLAG-tagged 
KLHL7 in HCT116 cells and immunoprecipitated 
the cell lysates using anti-FLAG antibody. As 
shown in Fig. 1A, Cul3 and Roc1 were 
co-immunoprecipitated with FLAG-KLHL7 (Fig. 
1A), indicating that KLHL7 forms Cul3-complex. 
To characterize the domain of KLHL7 
involved in the interaction with Cul3, KLHL7 
mutants lacking each domain were constructed 
(Fig. 1B). Wild-type KLHL7 and the mutant 
lacking the Kelch domain, which still has the BTB 
and BACK domains were able to bind to Cul3. On 
the other hand, the ΔBTB, ΔBTB-BACK and 
ΔBACK mutants lacking either or both the BTB 
and the BACK domains could not (Fig. 1C). These 
results suggest that KLHL7 associates with Cul3 
via its BTB and the BACK domains and both are 
required for Cul3 binding. 
Next, to examine the sub-cellular 
localization of KLHL7 and Cul3, HeLa cells 
transfected with FLAG-KLHL7 and HA-Cul3, 
were subjected to immunocytochemical analyses. 
As shown in Figure 1D, KLHL7 was mostly 
present as punctate structures which were also 
positive for Cul3 staining. While most of KLHL7 
was associated with Cul3, not all of the Cul3 
positive signals were stained with KLHL7, 
suggesting that only a subset of Cul3 is associated 
with KLHL7. Furthermore the punctate structures 
were not formed by any of the deletion mutants 
including the ΔKelch mutant (Supplemental Fig. 
1), indicating that Cul3 interaction is not sufficient 
for punctate formation. These results indicate that 
KLHL7 co-localizes with Cul3, and all of the 
domains are necessary for the punctate 
sub-cellular localization. 
KLHL7 forms a homo dimer through its BTB 
domains. Several members of the BTB family 
proteins, such as Keap1 and SPOP, form homo 
dimers (20,32). To investigate whether KLHL7 
dimerize, HA-tagged wild-type KLHL7 was 
co-expressed with FLAG-tagged KLHL7 
wild-type or deletion mutants into HCT116 cells, 
and their interactions were assessed by 
immunoprecipitation experiments, as shown in 
Figure 1E. As expected, wild-type KLHL7 could 
homo dimerize. The ΔBACK and ΔKelch mutants 
could still interact with wild-type KLHL7, 
whereas deletion of the BTB domain led to weak 
interaction, which was further weakened by the 
additional deletion of the BACK domain. These 
results suggest that the BTB domain is the primary 
domain necessary for KLHL7 dimerization, while 
the BACK domain, which is not essential for 
dimerization, is important for efficient 
dimerization. Because the ΔBACK mutant that 
could not interact with Cul3 (Fig. 1C) was still 
able to dimerize (Fig. 1E), the dimer formation of 
KLHL7 is not mediated indirectly by Cul3 
interaction. 
Cul3-KLHL7 has Ub ligase activity. Because 
KLHL7 forms Cul3-based complexes, we next 
investigated whether Cul3-KLHL7 has Ub ligase 
activity. If KLHL7 is indeed a part of a Ub ligase 
complex, the substrates of KLHL7 should 
accumulate in the ubiquitinated form when the 
proteasome is inhibited. To test this, HCT116 cells 
were transfected with FLAG-KLHL7 and HA-Ub, 
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and treated with the proteasome inhibitor MG132 
prior to immunoprecipitation. Immunoblot 
analyses with anti-HA antibody showed that 
ubiquitinated proteins interact with FLAG-KLHL7, 
and its amount increased drastically with 
proteasome inhibition (Fig. 2A). These data 
suggest that the ubiquitinated proteins that 
interacted with KLHL7 are targeted for 
proteasome degradation. There are several 
possibilities as to what the ubiquitinated proteins 
that accumulated with proteasome inhibition are. 
As strong bands were observed at the predicted 
molecular weight of ubiquitinated KLHL7 (approx. 
70 Kd), it may be possible that KLHL7 itself is a 
target. On the other hand, ubiquitin positive bands 
were also observed below the predicted molecular 
weight of ubiquitinated KLHL7, suggesting that 
those ubiquitinated proteins represent the 
authentic substrates of KLHL7.   
To test whether KLHL7 is indeed 
self-ubiquitinated, we examined the ubiquitinated 
state of KLHL7 by detecting FLAG-KLHL7 after 
HA-Ub immunoprecipitation. After proteasome 
inhibition, cell lysates of HCT116 cells expressing 
HA-Ub and FLAG-KLHL7 were 
immunoprecipitated with anti-HA antibody, and 
subsequently immunoblotted with anti-FLAG 
antibody to detect ubiquitinated KLHL7 (Fig. 2B). 
A single band of the estimated molecular weight 
of mono-ubiquitinated KLHL7 was strongly 
detected, whereas no ladder or smear was 
observed, indicating that the majority of KLHL7 
are only present as the mono-ubiquitinated form. 
These results suggest that the increase of Ub 
moiety associated with KLHL7 upon proteasome 
inhibition is mostly due to the accumulation of 
poly-ubiquitinated authentic substrates. 
We next examined the ligase activity of 
Cul3-KLHL7, in a substrate-independent in vitro 
ubiquitination assay (33,34). Cul3-KLHL7, 
purified from HCT116 cells by 
immunoprecipitation, was incubated with Ub 
activating enzyme E1, Ub conjugating enzyme E2 
and Ub in buffers with or without ATP (Fig. 2C). 
The amount of poly-Ub chain increased in a time 
dependent manner, indicating that Cul3-KLHL7 
has E3 ligase activity. 
Ub positive KLHL7 puncta increase with 
proteasome inhibition. KLHL7 and Cul3 
co-localized in punctate structures in the 
cytoplasm (Fig. 1D). KLHL7 also interacted with 
Ub, which increased with proteasome inhibition 
(Fig. 2A). Therefore we next sought to find out 
whether the KLHL7 puncta co-localize with Ub 
upon proteasome inhibition. Immunocytochemical 
analyses using the FK2 anti-multi-Ub antibody, 
which recognizes poly-Ub chains and 
poly-ubiquitinated substrates, indicated that 
KLHL7 co-localized with ubiquitinated proteins, 
and the co-localizing structures increased with 
proteasome inhibition (Fig. 3A). Similar analyses 
were done with K48-linked Ub chain specific 
antibody, and the co-localization of KLHL7 with 
K48-linked Ub chain increased with proteasome 
inhibition (Fig. 3B). On the other hand, no 
co-localization of KLHL7 with K63-linked Ub 
was seen, regardless of proteasome inhibition (Fig. 
3C). These results show that KLHL7 co-localizes 
with K48-linked poly-ubiquitinated proteins, but 
not with those with K63-linked poly-ubiquitin, 
suggesting that KLHL7 mediates the linkage of 
K48-linked, but not K63-linked poly-ubiquitin 
chain onto target proteins. The increase in 
Poly-Ub and K48-linked-Ub positive KLHL7 
puncta with proteasome inhibition, indicate that 
the substrates ubiquitinated by KLHL7 are 
targeted for proteasomal degradation. 
Ubiquitinated proteins can also be 
processed by the lysosome through the autophagic 
pathway. To investigate if the substrate of KLHL7 
is also degraded by the lysosome, the 
co-localization of KLHL7 and Ub were examined 
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under NH4Cl treatment (Fig. 4A,B). In contrast to 
proteasome inhibition, no accumulation in Ub 
positive KLHL7 puncta was seen with lysosome 
inhibition with NH4Cl. Furthermore, the 
involvement of the autophagic pathway was 
assessed by the co-localization of KLHL7 with 
GFP-tagged autophagosome marker LC3. To test 
this, we used ATG5+/+: GFP-LC3 and autophagy 
deficient ATG5-/-: GFP-LC3 MEFs, as negative 
control. No increase in the co-localization of 
KLHL7 with GFP-LC3 could be seen with 
MG132 or NH4Cl treatment, regardless of the 
increase in GFP-LC3 dots with lysosome 
inhibition (Supplemental Fig. 2). Taken together, 
these data suggest that KLHL7-associated 
ubiquitinated proteins are processed mostly, if not 
all, by the proteasome, and not the lysosome or 
LC3-dependent autophagy. 
AdRP causing A153V/T mutations disrupt Cul3 
interaction but not dimerization. Recently, three 
missense mutations, S150N, A153T/V in KLHL7 
were found in patients with adRP. All of these 
mutations are in the BACK domain, and while 
both S150 and A153 are conserved within 
vertebrate KLHL7 (Supplemental Fig. 3A), only 
A153 is conserved within other human 
BTB-BACK-Kelch proteins (Supplemental Fig. 
3B). As the BACK domain is necessary for the 
interaction with Cul3 but not for KLHL7 
dimerization (Fig. 1B, C, E), we examined if these 
mutants interact with Cul3 in HCT116 cells. 
KLHL7 S150N could still interact with Cul3 (Fig. 
5A lane 4), whereas the A153V and A153T 
mutants could not (Fig. 5A lanes 2 and3). We also 
investigated the sub-cellular localization of these 
missense mutations and their co-localization with 
Cul3. Immunocytochemical analyses in HeLa cells 
showed that KLHL7 S150N has similar 
sub-cellular localization with wild-type KLHL7, 
and co-localizes with Cul3 (Supplemental Fig. 4 
top). On the contrary, the sub-cellular localization 
of A153V and A153T was more peripheral than 
that of wild-type KLHL7, and co-localization with 
Cul3 was not as prominent (Fig. 1D, Fig. 5B, 
Supplemental Fig. 4 bottom). Taken together, 
these data suggest that A153 mutations in KLHL7 
attenuate its interaction and co-localization with 
Cul3. 
We next examined if the mutation in 
the A153 position affects the dimerization ability 
of KLHL7 by using the A153V mutant, as the 
BACK domain was important for efficient 
dimerization (Fig. 1E). We expressed 
FLAG-KLHL7 wild-type or A153V with 
HA-KLHL7 wild-type or A153V in HCT116 cells 
and immunoprecipitated the cell lysates with 
anti-FLAG antibody. KLHL7 A153V was able to 
form both a homo dimer, and a hetero dimer with 
wild-type KLHL7 (Fig. 5C). The S150N and 
A153T mutants could also bind to wild-type 
KLHL7 (Supplemental Fig. 5A). These data 
suggest that none of the adRP causative mutations 
interfere with KLHL7 dimerization. 
Immunocytochemical analyses showed that when 
both wild-type KLHL7 and A153V were 
expressed in HeLa cells, co-localization was 
observed in perinuclear punctate structures, 
resembling the sub-cellular localization of 
wild-type KLHL7 (Fig. 5D).  These data indicate 
that the sub-cellular localization of KLHL7 
A153V seems to be restored to that of wild-type 
KLHL7, by forming a hetero dimer. 
KLHL7 A153V does not inhibit Cul3-wild-type 
KLHL7 interaction. As KLHL7 A153V associates 
with wild-type KLHL7 but not directly with Cul3, 
we next examined the possibility that the hetero 
dimerization of KLHL7 A153V with wild-type 
KLHL7 inhibits the formation of Cul3-KLHL7 
complex. To examine this, we co-expressed 
KLHL7 A153V with wild-type KLHL7 and 
investigated the amount of Cul3 that 
co-immunoprecipitate with wild-type KLHL7 (Fig. 
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6A). Contrary to our expectations, the 
co-immunoprecipitation of Cul3 did not decrease 
even when KLHL7 A153V was co-expressed (Fig. 
6A. FLAG IP lanes 2 and 3). Moreover, a slight 
amount of Cul3 could be co-immunoprecipitated 
by KLHL7 A153V when the wild-type KLHL7 is 
co-expressed (Fig. 6A HA IP lanes 1 and 3). 
Similarly, A153T was also able to associate with 
Cul3 by the co-expression of wild-type KLHL7 
(Supplemental Fig. 5B). Taken together, it seems 
that though KLHL7 A153V cannot directly 
interact with Cul3, the mutation in one molecule 
of the KLHL7 dimer does not inhibit the assembly 
of Cul3-KLHL7 in a dominant negative manner. 
KLHL7 A153V attenuates the E3 Ligase activity of 
Cul3-KLHL7. To understand the effect of KLHL7 
with mutations in A153 in the Cul3-KLHL7 
complex, we next assessed whether the 
incorporation of KLHL7 A153V affects the E3 
ligase activity of Cul3-KLHL7. FLAG-KLHL7 
and HA-Ub were transfected with increasing 
amounts of 6Myc-KLHL7 A153V, and 
ubiquitinated proteins associated with 
FLAG-KLHL7 were examined. Under proteasome 
inhibition, the amount of Ub that associated with 
wild-type KLHL7 decreased in proportion to the 
co-expressed KLHL7 A153V, even though there 
was no change in the amount of 
co-immunoprecipitated Cul3 and FLAG-KLHL7 
(Fig. 6B). These data indicate that the A153V 
mutant decreases the E3 activity of Cul3-KLHL7. 
 
DISCUSSION 
 
In this study, we have shown that 
KLHL7 dimerizes, and forms a novel Cul3-based 
E3 ligase. Though the RP causative KLHL7 
S150N mutant did not have obvious effects, and 
remains to be further investigated, our study 
provides insights into how the A153 mutations 
affect the ligase activity of Cul3-KLHL7. The 
A153V and A153T mutants have the putative 
substrate binding Kelch, and the dimerization 
BTB domains intact. Therefore it is conceivable 
that the homo dimers would be able to bind onto 
its authentic substrate. As the A153 mutants could 
not directly associate with Cul3, the substrate 
bound to the mutant homo dimer would not be 
recruited to the Cul3-Roc1 complex for 
ubiquitination (Fig 6C right). The sub-cellular 
localization of A153V and A153T mutants 
differed from that of wild-type, suggesting that 
Cul3-binding and subsequent ubiquitination of the 
substrate may regulate the localization of KLHL7. 
Consistent with this notion, none of the deletion 
mutants formed such punctate structures 
(Supplemental Fig. 1), including the ΔKelch 
mutant that associates with Cul3. 
Although KLHL7 A153V and A153T 
did not interact with Cul3, co-expression of 
wild-type KLHL7 enabled the mutants to associate 
with Cul3. Furthermore, the localization of 
KLHL7 A153V returned to normal appearance 
with the co-expression of wild-type KLHL7. 
These results suggest that the mutants can be 
incorporated into the Cul3 complex through the 
dimerization with wild-type KLHL7. However, 
the amount of ubiquitinated proteins associated 
with Cul3-KLHL7 greatly diminished when the 
A153V mutant was present in the complex. This 
decrease in the ligase activity of Cul3-KLHL7 can 
be attributed to the change in the conformation of 
the complex. As the hetero dimer would only be 
able to recruit one molecule of Cul3 with the 
wild-type KLHL7, the overall number of the 
catalytic subunit Roc1 incorporated in the 
Cul3-KLHL7 complex will decrease (Fig. 6C left 
and middle). Several previous studies have also 
shown that CRLs take dynamic conformations 
(35,36), the flexibility of which may be 
rate-limiting for ligase activity. Dimerizations of 
substrate recognition proteins may influence the 
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positioning of the substrate within the complex, as 
suggested by the analysis of the F-box protein 
Cdc4. The dimerization of Cdc4 does not 
influence the affinity with its substrate Sic1, but 
seems to influence the positioning of the substrate 
within the ligase complex (37). KLHL7 may 
function likewise, and the incorporation of the 
A153 mutant into the Cul3-KLHL7 complex may 
result in a change in the flexibility or the correct 
positioning of the substrate, necessary for efficient 
substrate ubiquitination. The attenuation of 
Cul3-KLHL7 ligase activity by homo and hetero 
dimers of mutant KLHL7, will lead to the 
accumulation of the substrates, which could result 
in cellular toxicity. 
Cul3-KLHL7 formed punctate 
structures that resemble vesicles or inclusion 
bodies. Inclusion bodies, which secludes 
misfolded or unnecessary proteins, are degraded 
by the proteasome and autophagic pathways (38). 
In our study, K48-linked poly-Ub positive KLHL7 
puncta, increased with proteasome inhibition, 
suggesting that proteins ubiquitinated by 
Cul3-KLHL7 are degraded by the proteasome. On 
the other hand, the puncta did not increase with 
NH4Cl treatment (Fig. 4) nor co-localize with the 
autophagosome marker LC3 (Supplementary Fig. 
2) and the lysosome marker LAMP1 (data not 
shown), making it unlikely that these puncta are 
processed by the lysosomal pathways. 
RP is a heterogeneous disease, which is 
caused by defects in different biochemical 
cascades(28,29). Mutations in membrane proteins 
such as RDS and the photon receptor RHO are 
known to cause RP. Several genes related to 
protein trafficking and the cytoskeletal structures, 
such as FSCN2, that binds to actin (39,40) and 
microtuble associated RP1 (41), as well as 
MYO7A (42-45) involved in intracellular 
trafficking, have also been reported as RP 
causative genes. Ub modification is known to be 
important for the quality control, internalization 
and multivesicular-body (MVB) sorting of 
membrane proteins. It is also involved in the 
regulation of vesicle sorting and transport along 
the cytoskeletal structures (46,47). KLHL7 may be 
involved in the regulation of any of these 
processes, however, how it is involved remains to 
be elucidated. 
In summary, we present KLHL7 as a 
novel substrate recognition subunit of Cul3-based 
Ub ligase complex. Moreover, we have shown that 
the adRP causative A153V mutation inhibits the 
ligase activity of Cul3-KLHL7 in a dominant 
negative manner. Future studies should focus on 
determining the substrate and the components of 
the Cul3-KLHL7 puncta, which will undoubtedly 
become the key to understanding the physiological 
role of KLHL7. 
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FIGURE LEGENDS 
 
Fig. 1. KLHL7 forms a Cul3-based complex. A, HCT116 cells transfected with FLAG-KLHL7 
or mock vectors were immunoprecipitated with anti-FLAG antibody and immunoblotted with antibodies 
to Cul3, Roc1 and FLAG as indicated. B, Schematic representations of KLHL7 (wild-type (WT) and 
deletion mutants). C, Deletion mutants of FLAG-tagged KLHL7 were expressed in HCT116 cells and 
immunoprecipitated with anti-FLAG antibody, and immunoblotted with anti-Cul3 and anti-FLAG 
antibodies. Non-specific bands are indicated with an asterisk (*). D, HeLa cells cultured on coverslips 
were transfected with HA-Cul3 and FLAG-KLHL7. The cells were fixed and stained with anti-HA and 
anti-FLAG antibodies and Hoechst 33342. Scale bar, 20 µM. E, Deletion mutants of FLAG-tagged 
KLHL7 were co-expressed with HA-tagged full length KLHL7 in HCT116 cells, and immunoprecipitated 
with anti-FLAG and anti-HA antibodies. The immunoprecipitates were blotted with anti-HA and 
anti-FLAG antibodies. 
 
Fig. 2. Cul3-KLHL7 is an E3 Ligase. A, FLAG-KLHL7 or mock vectors were co-expressed 
with HA-Ub in HCT116 cells and treated with 20 µM MG132 (+) or DMSO (-) prior to harvesting. Cell 
lysates were immunoprecipitated with anti-FLAG antibody and blotted with anti-FLAG and anti-HA 
antibodies. B, FLAG-KLHL7 was co-expressed with HA-Ub in HCT116 cells. After 20 µM MG132 
treatment, the cell lysates were immunoprecipitated with anti-HA antibody and subjected to 
immunoblotting with anti-HA and anti-FLAG antibodies. C, in vitro ubiquitination assay using 
Cul3-KLHL7 complex immunopurified from HCT116 cells. Cul3-KLHL7 was incubated with 
recombinant E1 (UBE1), E2 (UBC4) and Ub, with or without ATP at 30 ℃. The reaction was stopped at 
the indicated times and then immunoblotted with anti-FK2 Ub antibody. 
 
Fig. 3. The Ub positive KLHL7 puncta increase with proteasome inhibition. A, B and C, HeLa 
cells cultured on coverslips were transfected with FLAG-KLHL7 and treated with either 20 µM of 
MG132 or DMSO, and stained with antibodies to FLAG (red) and Ub (green) with anti-FK2 (A), anti-K48 
(B) and anti-K63 (C). The nucleus was stained with Hoechst 33342. Scale bars, 20 µM. 
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Fig. 4. Ub positive KLHL7 does not increase by lysosome inhibition. A and B, HeLa cells 
cultured on coverslips were transfected with FLAG-KLHL7 and treated with or without NH4Cl for 
lysosome inhibition, and stained with antibodies to FLAG and Ub with anti-FK2 (A) and anti-K48 (B). 
The nucleus was detected with Hoechst 33342. Scale bars, 20 µM. 
 
Fig. 5. A153 mutations of KLHL7 inhibit Cul3 interaction but not dimerization. A, HCT116 
cells were transfected with either FLAG-KLHL7 wild-type or missense mutants. The cell lysates were 
immunoprecipitated with anti-FLAG antibody and immunoblotted with anti-Cul3 and anti-FLAG 
antibodies. B, HeLa cells cultured on coverslips were transfected with HA-Cul3 and FLAG-KLHL7 
A153V. The cells were fixed and stained with anti-HA and anti-FLAG antibodies and Hoechst 33342. C, 
FLAG-KLHL7 (wild-type (WT) and A153V (mt)) and HA-KLHL7 (wild-type (WT) and A153V (mt)) 
were expressed in HCT116 cells as indicated. FLAG-KLHL7 was immunoprecipitated with anti-FLAG 
antibody and immunoblotted with anti-HA and anti-FLAG antibodies. D, HeLa cells on coverslips were 
transfected with FLAG-KLHL7 and HA-KLHL7 A153V. After fixation, cells were stained with 
anti-FLAG and anti-HA antibodies and Hoechst 33342. Scale bars, 20 µM. 
 
Fig. 6. KLHL7 A153V attenuates Cul3-KLHL7 ligase activity. A, HCT116 cells were transfected 
with FLAG-KLHL7 and HA-KLHL7 A153V as indicated. The cell lysates were immunoprecipitated with 
anti-FLAG or anti-HA antibodies and immunoblotted with anti-Cul3, anti-HA and anti-FLAG antibodies. 
B, HCT116 cells were transfected with FLAG-KLHL7, HA-Ub, and increasing amounts of 6Myc-KLHL7 
A153V. The cells were treated with 20 µM MG132 for 1 hr prior to harvesting, and immunoprecipitated 
with anti-FLAG antibodies. Immunoblot analyses were done using anti-HA, anti-Myc, anti-Cul3 and 
anti-FLAG antibodies. C, Molecular models of KLHL7-mediated ubiquitination. KLHL7 is indicated in 
green: wild-type and yellow: A153V or A153T, and the substrate as S. The domains of KLHL7 are 
indicated as BB: BTB, BK: BACK and Klh: Kelch. The wild-type KLHL7 homo dimer binds to two sets 
of Cul3/Roc and targets the substrates for ubiquitination (Left). The hetero dimer of wild-type and 
A153V/T mutant can only bind to one set of Cul3/Roc1, and may ubiquitinate one of the two substrates, if 
not at all (middle). The A153V/T mutant homo dimer cannot bind to Cul3/Roc1 and fails to target the 
substrates for ubiquitination (right).  
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